Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -708.48% is 275% below its 5-year average of -188.89%, near the low end of its 5-year range (-708.48%–1.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 52.77% below its 12-month average of -463.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -708.48%.
RETURN ON EQUITY (ROE)
-708.48%
RETURN ON EQUITY (ROE) AVG TTM
-463.74%
RETURN ON EQUITY (ROE) AVG 3Y
-503.08%
RETURN ON EQUITY (ROE) AVG 5Y
-188.89%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.77%
CURRENT VS 3Y AVG
-40.83%
CURRENT VS 5Y AVG
-275.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.40%
median of 667 covered companies
CURRENT VS SECTOR MEDIAN
-1653.66%
vs the sector median at left
Envoy Medical, Inc.
Market Cap
$51.33M
Return on Equity (ROE)
-708.48%
TTM Avg
-463.74%
3Y Avg
-503.08%
5Y Avg
-188.89%
Market Cap
$51.42M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
Market Cap
$51.07M
Return on Equity (ROE)
-76.82%
TTM Avg
-798.41%
3Y Avg
-485.96%
5Y Avg
-324.45%
Market Cap
$51.61M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$51.05M
Return on Equity (ROE)
N/A
TTM Avg
296.81%
3Y Avg
-175.08%
5Y Avg
-1071.79%
Market Cap
$50.51M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
Market Cap
$50.48M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$51.91M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$50.37M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Envoy Medical, Inc. (COCH) | $51.33M | -708.48% | -463.74% | -503.08% | -188.89% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | -278.89% | -162.92% | 25.71% | 0.37% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.07M | -76.82% | -798.41% | -485.96% | -324.45% |
| biote Corp. (BTMD)vs › | $51.61M | N/A | -24.59% | -14.57% | 93.61% |
| Clene Inc. (CLNN)vs › | $51.05M | N/A | 296.81% | -175.08% | -1071.79% |
| INmune Bio, Inc. (INMB)vs › | $50.51M | -90.44% | -163.19% | -112.62% | -86.58% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.48M | N/A | 31.64% | 119.26% | -26.51% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $51.91M | -36114.03% | -31.09% | -15.54% | -12.44% |
| Celularity Inc. (CELU)vs › | $50.37M | N/A | -206.96% | -221.50% | -349.91% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | -52.72% | -32.48% | -92.81% | -85.98% |
ROE
-708.5%
ROA
-97.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -708.48% |
| 2026-03-31 | -219.00% |
| 2023-09-30 | -581.77% |
| 2022-09-30 | -2.24% |
| 2022-06-30 | -0.56% |
| 2022-03-31 | -0.16% |
| 2021-12-31 | -0.06% |
| 2021-09-30 | 1.14% |
